'Buying time' for natural killer cells could enhance cancer immunity
The Walter and Eliza Hall Institute of Medical Research News Jan 26, 2017
A team of researchers from Australia and France have uncovered new insights into how to prolong the lifespan of the bodyÂs disease–fighting natural killer (NK) cells.
The finding offers fresh clues about how best to harness NK cells to improve their disease–fighting function. This may have particular importance for cancer immunotherapy, Âbuying more time for NK cells to detect and destroy cancer cells.
The Melbourne team led by Dr Nick Huntington from the Walter and Eliza Hall Institute along with collaborators from Centre of Immunology in France, Professor Eric Vivier and Professor Sophie Ugolini, made the discovery by investigating factors that control NK cell function.
The research was published in The Journal of Experimental Medicine.
Dr Huntington said the research revealed that a protein called BCL–2 was particularly important for controlling the reservoir of NK cells in our body. BCL–2 is a so–called Âpro–survival protein that makes normal immune cells survive for extended periods.
ÂWe have been very interested in understanding which factors control the lifespan of NK cells, Dr Huntington said. ÂWe had previously identified a protein related to BCL–2, called MCL–1, which was critically required for all NK cell survival. This new study now shows that BCL–2 Âteams up with MCL–1 and both these proteins crucially determine NK cell survival in our body, and the majority of NK cells died following a reduction in the levels of BCL–2.
ÂImportantly, we were able to prevent NK cell death when BCL–2 levels were low by using a hormone–like protein or cytokine called IL–15. Boosting NK cell numbers by treating them with IL–15 may be a valuable new approach to boosting our immunity to viral infections or cancer. On the flipside, targeting this growth factor or BCL–2 could reduce NK cell numbers and offer potential for therapies for immune disorders such as some types of autoimmune diseases, sepsis or graft versus host disease, a side effect of bone marrow transplants.
The teamÂs research also identified that NK cells may be vulnerable to new medicines that inhibit BCL–2, which are also becoming widely tested as anti–cancer treatments.
ÂOur research has identified that adding cytokines could be a novel way to protect NK cells from the effect of BCL–2 inhibitors, maintaining healthy NK cell numbers in people undergoing cancer therapy, Dr Huntington said.
Go to Original
The finding offers fresh clues about how best to harness NK cells to improve their disease–fighting function. This may have particular importance for cancer immunotherapy, Âbuying more time for NK cells to detect and destroy cancer cells.
The Melbourne team led by Dr Nick Huntington from the Walter and Eliza Hall Institute along with collaborators from Centre of Immunology in France, Professor Eric Vivier and Professor Sophie Ugolini, made the discovery by investigating factors that control NK cell function.
The research was published in The Journal of Experimental Medicine.
Dr Huntington said the research revealed that a protein called BCL–2 was particularly important for controlling the reservoir of NK cells in our body. BCL–2 is a so–called Âpro–survival protein that makes normal immune cells survive for extended periods.
ÂWe have been very interested in understanding which factors control the lifespan of NK cells, Dr Huntington said. ÂWe had previously identified a protein related to BCL–2, called MCL–1, which was critically required for all NK cell survival. This new study now shows that BCL–2 Âteams up with MCL–1 and both these proteins crucially determine NK cell survival in our body, and the majority of NK cells died following a reduction in the levels of BCL–2.
ÂImportantly, we were able to prevent NK cell death when BCL–2 levels were low by using a hormone–like protein or cytokine called IL–15. Boosting NK cell numbers by treating them with IL–15 may be a valuable new approach to boosting our immunity to viral infections or cancer. On the flipside, targeting this growth factor or BCL–2 could reduce NK cell numbers and offer potential for therapies for immune disorders such as some types of autoimmune diseases, sepsis or graft versus host disease, a side effect of bone marrow transplants.
The teamÂs research also identified that NK cells may be vulnerable to new medicines that inhibit BCL–2, which are also becoming widely tested as anti–cancer treatments.
ÂOur research has identified that adding cytokines could be a novel way to protect NK cells from the effect of BCL–2 inhibitors, maintaining healthy NK cell numbers in people undergoing cancer therapy, Dr Huntington said.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
